×
About 46 results

ALLMedicine™ Hyperbilirubinemia Center - News

Easy Assessment Predicts Significant Neonatal Hyperbilirubinemia
https://www.medpagetoday.com/pediatrics/generalpediatrics/7932

Jan 11th, 2008 - Action Points Explain to interested patients that the study found that predischarge bilirubin levels and gestational age predict which infants are at high risk of developing hyperbilirubinemia serious enough to warrant treatment. Point out that the cost-benefit balance of a screening program based on this model has not been calculated. PHILADELPHIA, Jan. 11 -- Newborns at risk for severe hyperb...

Enasidenib May Achieve Remission in IDH2 Mutant Positive AML Patients
https://www.medpagetoday.com/hematologyoncology/hematology/65902

Jun 9th, 2017 - Action Points Enasidenib is effective in inducing remission in patients with relapsed or treatment-resistant acute myeloid leukemia (AML), and an isocitrate dehydrogenase-2 (IDH2) gene mutation. Note that enasidenib treatment was generally well-tolerated, and 24% of patients had treatment-related serious adverse events, including IDH differentiation syndrome, leukocytosis, tumor lysis syndrome,...

Jaundiced Babies Rarely Develop Neurologic Damage
https://www.medpagetoday.com/gastroenterology/generalhepatology/3231

May 4th, 2006 - Action Points Advise parents that this study suggests hyperbilirubinemia can be effectively treated with phototherapy and does not result in long-term neurological damage in the vast majority of cases. Be aware that the American Academy of Pediatrics recommends that treatment be given to newborns to keep total serum bilirubin levels from exceeding 25 mg/dL. SAN FRANCISCO, May 4 — The risk of a ...

Maternal Hyperglycemia Tied to High Fetal Insulin
https://www.mdedge.com/obgyn/article/49904/obstetrics/maternal-hyperglycemia-tied-high-fetal-insulin
Mary Ann Moon

Maternal glucose levels that were high but below the diagnostic threshold for gestational diabetes were strongly associated with high fetal insulin levels and birth weights in an international study of 23,316 pregnant women. There were also weaker—but still significant—associations between maternal hyperglycemia that fell short of overt gestational diabetes and a host of neonatal problems: hypo.

Tx Lowers Some Mild Gestational Diabetes Risks
https://www.mdedge.com/obgyn/article/50850/obstetrics/tx-lowers-some-mild-gestational-diabetes-risks
Mary Ann Moon

Treating mild gestational diabetes lowered the risks of fetal overgrowth, shoulder dystocia, cesarean delivery, and gestational hypertension, as well as decreasing maternal weight gain, based on a study of almost 1,000 women. However, treating mild gestational diabetes did not improve the composite primary outcome of neonatal mortality, hypoglycemia, hyperbilirubinemia, hyperinsulinemia, and bi.

Treatment of Mild Gestational Diabetes Shows Modest Benefit
https://www.mdedge.com/familymedicine/article/29995/endocrinology/treatment-mild-gestational-diabetes-shows-modest-benefit
Family Practice News; Mary Ann Moon

Treating mild gestational diabetes lowered the risks of fetal overgrowth, shoulder dystocia, cesarean delivery, and gestational hypertension, as well as decreasing maternal weight gain, according to a report in almost 1,000 women. However, treating mild gestational diabetes did not improve the composite primary outcome of neonatal mortality, hypoglycemia, hyperbilirubinemia, hyperinsulinemia, a.

Fluconazole Reduces Candidiasis in VLBW Infants
https://www.mdedge.com/pediatrics/article/39399/infectious-diseases/fluconazole-reduces-candidiasis-vlbw-infants
Jane Salodof MacNeil

SAN FRANCISCO — Fluconazole prophylaxis reduced fungal infections and mortality in very low-birth-weight infants at two neonatal intensive care units in retrospective studies that were presented during the annual meeting of the Pediatric Academic Societies. Incidence of invasive candidiasis in very low-birth-weight (VLBW) infants went from 6.

FDA Warns About Liver Risks Of Recalled Dietary Supplement
https://www.mdedge.com/familymedicine/article/29488/gastroenterology/fda-warns-about-liver-risks-recalled-dietary
Family Practice News; Elizabeth Mechcatie

Reports of severe liver injuries—including one fatality—associated with Hydroxycut brand dietary supplements have prompted a nationwide product recall, the Food and Drug Administration announced last month. The products are marketed as weight-loss aids, energy-enhancers, low-carbohydrate diet aids, and diuretics.

Maternal Hyperglycemia Tied to High Fetal Insulin, Birth Weight
https://www.mdedge.com/familymedicine/article/29970/womens-health/maternal-hyperglycemia-tied-high-fetal-insulin-birth
Family Practice News; Mary Ann Moon

Maternal glucose levels that were high but below the diagnostic threshold for gestational diabetes were strongly associated with high fetal insulin levels and birth weights in a large international study. There were also weaker—but still significant—associations between maternal hyperglycemia that fell short of overt gestational diabetes, as well as a host of neonatal problems that included hyp.

FDA Staff: Neonatal Jaundice Drug Effective, But Safety Uncertain
https://www.medpagetoday.com/pediatrics/generalpediatrics/72646

May 2nd, 2018 - WASHINGTON -- Just one dose of a drug called stannsoporfin significantly reduced bilirubin levels in newborns with severe hyperbilirubinemia, but at the potential cost of long-term neurological risk, according to an FDA briefing document prepared for a Thursday advisory committee meeting. The FDA's Gastrointestinal Drugs Advisory Committee and the Pediatric Advisory Committee will meet jointly ...

Can insulin plus metformin improve pregnancy outcomes in women with type 2 diabetes?
https://www.mdedge.com/fedprac/article/214703/obstetrics/can-insulin-plus-metformin-improve-pregnancy-outcomes-women-type-2/page/0/1?channel=53

Dec 23rd, 2019 - Currently, the multisite MOMPOD trial (Medical Optimization of Management of T2DM Complicating Pregnancy) is randomizing 950 women to insulin plus 1,000 mg metformin twice daily or insulin plus placebo. The primary outcome of the trial is a composite of pregnancy loss, preterm birth, birth injury, neonatal hypoglycemia, or hyperbilirubinemia.

Aim to Delay Delivery Until 39 Weeks Regardless of Fetal Lung Maturity
https://www.mdedge.com/internalmedicine/article/20202/womens-health/aim-delay-delivery-until-39-weeks-regardless-fetal-lung
Sharon Worcester

Jan 25th, 2011 - Neonates who are delivered at 36-38 weeks’ gestation after fetal lung maturity is confirmed have nearly double the risk of adverse outcomes, compared with neonates delivered at 39 or 40 weeks, a large retrospective cohort study has shown. The mean birth weight in 459 neonates with confirmed lung maturity who were delivered at 36-38 weeks’ gestation was 3,017 g, compared with 3,362 g in 13,339 n.

Checkpoint inhibition after HiDAC shows promise in AML
https://www.mdedge.com/hematology-oncology/article/163748/aml/checkpoint-inhibition-after-hidac-shows-promise-aml/page/0/2

Apr 18th, 2018 - The most common overall toxicities included febrile neutropenia in 70% of patients; transaminitis (including one grade 3 case) in 50%, hyperbilirubinemia in 35%, and fatigue, increased alkaline phosphatase, and rash in 25% each. Novel therapies for relapsed/refractory AML are urgently needed, and these early results demonstrated the safety and feasibility of adding pembrolizumab after HiDAC che.

Glyburide failed to show noninferiority in gestational diabetes
https://www.mdedge.com/familymedicine/article/164700/diabetes/glyburide-failed-show-noninferiority-gestational-diabetes
Clinical Endocrinology News; Amy Karon

May 2nd, 2018 - A randomized, multicenter trial failed to find glyburide noninferior to insulin for treatment of gestational diabetes, investigators reported. The composite rate of macrosomia, neonatal hypoglycemia, and hyperbilirubinemia was 27.

FDA panel backs antifungal for invasive aspergillosis, mucormycosis
https://www.mdedge.com/familymedicine/article/96615/pulmonology/fda-panel-backs-antifungal-invasive-aspergillosis/page/0/1
CHEST Physician;

Jan 23rd, 2015 - Differences in adverse events included lower rates of hepatobiliary disorders, including hyperbilirubinemia, abnormal hepatic function, and jaundice (9% vs. 16%); skin and subcutaneous tissue disorders, including rash, erythema, and drug eruption (34% vs 43%) associated with isavuconazonium, compared with voriconazole.

FDA panel backs approval of new protease inhibitor for hepatitis C
https://www.mdedge.com/familymedicine/article/78503/infectious-diseases/fda-panel-backs-approval-new-protease-inhibitor/page/0/1
Family Practice News;

Oct 25th, 2013 - In phase III studies, fatigue, headache, and influenzalike illness, associated with PR, were the most common adverse events. The only deaths reported were in three patients treated with simeprevir after they stopped taking the drug, but were not considered related to the drug.

Neonatal hyperbilirubinemia: An evidence-based approach
https://www.mdedge.com/familymedicine/article/193251/pediatrics/neonatal-hyperbilirubinemia-evidence-based-approach/page/0/3
MDedge Family Medicine;

Jan 28th, 2019 - The US Preventative Services Task Force, however, found insufficient evidence to recommend universal screening for infants ≥35 weeks’ gestation. 27 The main rationale for their “I” recommendation was that although screening can identify infants at risk of developing severe hyperbilirubinemia, there is no clear evidence that identifying and treating elevated bilirubin levels results in the preven.

A Curious Case of Anti-D Antibody Titer
https://www.medscape.com/viewarticle/712668_7

Fetal Surveillance for RhD Alloimmunization RhD alloimmunization occurs because RhIG was not administered, the dose was inadequate, or, despite RhIG administration, maternal production of anti-D antibody occurs. RhD alloimmunization exposes future pregnancies with RhD-positive fetuses to hemolytic disease of the fetus and newborn. Consequences of hemolytic disease of the fetus and newborn may b...

Delayed Clamping of the Umbilical Cord: A Review with Implications for Practice
https://www.medscape.com/viewarticle/708616_4

Potential Adverse Effects of Delayed Cord Clamping It has been postulated that delayed cord clamping may increase rates of hyperbilirubinemia, polycythemia, and transient tachypnea in the newborn or maternal hemorrhage. However, delayed cord clamping has never been proven to increase the rate of neonatal symptomatic disease or maternal blood loss.[3,6,9] Polycythemia Polycythemia is defined as ...

Malpractice Case: Be Aware When Follow-up Requires Extra Steps
https://www.medscape.com/viewarticle/924898_1

Mar 1st, 2020 - Some communications among a patient's healthcare team may not be as direct as one would prefer, but they may still trigger a duty on the recipient to follow up. Dr P, a general pediatrician, was called to attend a vaginal delivery of a newborn with a history of three fetal transfusion surgeries. Dr P ordered for his newborn patient a transcutaneous bilirubin test, and when that test revealed hy...